AGEN - 2 Falling-Knife Stocks Actually Worth Buying Right Now
November has been brutal for biotech stocks. The SPDR S&P Biotech ETF has dropped by 5.1% just 2 1/2 weeks into the month. This bellwether biotech exchange-traded fund (ETF), in turn, has now declined by a hefty 12.7% so far this year. While no single culprit can be fingered as the sole cause of biotech's year-end sell-off, the cryptocurrency craze and tax-loss selling are probably high up on the list.
In short, investors have seemingly favored high-flying cryptocurrencies as their go-to asset class for risky growth plays of late, a niche formerly occupied almost exclusively by developmental-stage biotechs. On the tax-loss-selling side of things, it's no secret that biotechs -- especially small-cap companies -- haven't performed well this year for the most part, making them top candidates for tax-loss harvesting.
This downturn, however, presents some intriguing buying opportunities. Which biotechs have the best chance of rebounding soon? Adaptimmune Therapeutics (NASDAQ: ADAP) and Agenus (NASDAQ: AGEN) have both turned into so-called "falling-knife stocks" this month (see chart below). Here's why savvy investors might want to take advantage of this sizable pullback in these two clinical-stage biotech stocks .
For further details see:
2 Falling-Knife Stocks Actually Worth Buying Right Now